

03 August 2021

CXBLADDER CONTINUES TO EXTEND COVERAGE OVER NZ PUBLIC HEALTHCARE PROVIDERS

Taranaki District Health Board adopts full suite of Cxbladder tests

Cancer diagnostics company, Pacific Edge Limited (NZX: PEB) has reached commercial agreement with Taranaki District Health Board (DHB) for the use of the Cxbladder products for use across the clinical pathway in the detection, management and monitoring of bladder cancer patients, further extending the national coverage of Cxbladder delivered through New Zealand's public healthcare providers.

Taranaki DHB is based in New Plymouth and covers an area including Stratford and Hawera, serving a population of over 124,000, with a higher than average number of people aged 50 years or older, a predominantly rural population with a strong Maori presence.

Under the agreement, Taranaki DHB will provide access to Cxbladder Triage, Detect, Resolve and Monitor tests for patients throughout the region, with Cxbladder urine sampling systems sent to Taranaki Pathology collection locations where the specimen collection will be carried out for ease of access.

Brent Pownall, VP Commercial and Franchise at Pacific Edge, said: "This agreement furthers the reach of Cxbladder into regional New Zealand, helping physicians with their evaluation of patients who present with haematuria (blood in the urine) at our busy public hospitals. Pacific Edge's suite of Cxbladder products are now well-placed to extend their coverage under a national clinical pathway as New Zealand's health system consolidates towards the Maori Health Authority and Health NZ next year."

ENDS

For more information contact:

David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800

OVERVIEW www.pacifedge.co.nz www.pacifedgedx.com

Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management of urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company's products have been tested and validated in international multi-centre clinical studies.

ABOUT Cxbladder Triage www.cxbladder.com

Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com

Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a patients' urine. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com

Cxbladder Monitor allows urologists to monitor bladder cancer patients for recurrence of the disease. Bladder cancer has a recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com

Cxbladder Resolve identifies those patients who are likely to have aggressive or more advanced bladder cancer. Cxbladder Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage, Detect), is designed to assist clinicians by accurately identifying patients with a high probability of having high grade or late stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritised for further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.